⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

March 1, 2026ESMO rare cancers.Open Access

156P Systemic therapy effectiveness in metastatic non-uterine leiomyosarcoma: A decade of real-world outcomes from an Indian cohort

A. Shah S.S.K.R. Addagalla S. Rath Vivek K. Srigadha B. Rekhi N. Khanna M. Ramadwar P. Panjwani A. Janu S. Laskar J.J. Manjali S.K. Ghosh M. Goel S. Patkar P. Nayak S. Yadav Manish Pruthi Prateek Hegde P.G. Bhargava

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness and safety of cabozantinib in patients with metastatic non-uterine leiomyosarcoma.
Retrospective cohort analysis of 16 patients
Assessment of survival outcomes including PFS and overall survival
QoL measured using the EORTC QLQ-C30 at baseline and 3 months
Mutation analysis to identify primary and secondary mutations
3-month overall response rate (ORR) was 20.0%
Median progression-free survival (PFS) was 4.0 months
Grade 3 adverse events included hand-foot skin reaction (20%) and hypertension (20%)
Quality of life showed non-significant worsening in several areas.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Real-world outcomes report cabozantinib's effectiveness in metastatic non-uterine leiomyosarcoma, indicating potential for further evaluation.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shah et al. (2026) studied this question.

synapsesocial.com/papers/69b257ec96eeacc4fcec701c https://doi.org/10.1016/j.esmorc.2026.100362

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1155P Soft tissue tumors and radiotherapy patterns: A retrospective reviewCohort Study · 2026
2158P Clinico-epidemiological profile, systemic therapy effectiveness, and survival outcomes in localised non-uterine leiomyosarcoma: Real-world evidence from IndiaClinical Trial · 2026
3A phase II study of cabozantinib in metastatic or unresectable refractory gastrointestinal stromal tumour(GIST): a single-centre study from IndiaHuman Clinical Trial · 2026
4157P Real-world evidence on the effectiveness and safety of trabectedin plus low-dose radiotherapy in sarcoma: A retrospective analysisCohort Study · 2026
576P Leiomyosarcoma: Reviewing first-line options2024
6137P Predicting survival outcomes in solitary fibrous tumours: A retrospective clinicopathological and molecular cohort studyCohort Study · 2026
759MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts2024 · 1 citations
8Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing ResultsCohort Study · 2017 · 125 citations
9Palliative systemic chemotherapy in peritoneal mesothelioma: a retrospective efficacy analysis of the RENAPE databaseESMO rare cancers. · 2026
10Using liver-directed therapies as backbone for combination-treatments in metastatic uveal melanomaESMO rare cancers. · 2026

More from ESMO rare cancers.

More from Tata Memorial Hospital